Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01889 (ankylosing spondylitis)
 5,717 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sulindac is a new non-steroidal drug which is currently available for the treatment of rheumatoid arthritis, osteo-arthritis and ankylosing spondylitis throughout the world. We have recently assessed on open trial of this drug in acute gout arthritis of 26 patients (16 men and ten women). Their ages ranged from 40 to 62 years. All the patients entered in the study provided the fulfilled rigid criteria. Patients received 400 mg in two separate doses in the morning and evening for seven days. There was a dramatic improvement in the joint pain in 15 patients in the first 24 hours and only one after 48 hours, swelling and tenderness improved after four days. No significant side-effects and no significant changes in any of the laboratory tests were observed. Our conclusion is that sulindac is a very useful drug in the treatment of acute gout arthritis.
 ...
PMID:Sulindac in the treatment of acute gout arthritis. 716 1

Sulindac is a sulfoxide prodrug that, in vivo, is converted to the metabolites sulindac sulfide and sulindac sulfone. It is therapeutically used as an anti-inflammatory and analgesic in the symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. In addition to its anti-inflammatory properties, sulindac and its metabolites have been shown to have an important role in the prevention of colonic carcinogenesis. Although the inhibition of prostaglandin synthesis constitutes the primary mechanism of action of sulindac, it is well known that reactive oxygen species (ROS) and reactive nitrogen species (RNS) are implicated in the pathophysiology of inflammation and cancer. Thus, the aim of this study was to evaluate the scavenging activity of sulindac and its sulfone and sulfide metabolites for an array of ROS (HO*, O2(*-), and HOCl) and RNS (*NO and ONOO-) using in vitro systems. The results we obtained demonstrate that the metabolism of sulindac increases its scavenging activity for all RNS and ROS studied, notably with regard to the scavenging of HOCl. These effects may strongly contribute to the anti-inflammatory and anticarcinogenic efficacy that has been shown for sulindac.
 ...
PMID:The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. 1457 4